Literature DB >> 17039315

Leflunomide-related acute interstitial pneumonia in two patients with rheumatoid arthritis: autopsy findings with a mosaic pattern of acute and organizing diffuse alveolar damage.

Sae Ochi1, Masayoshi Harigai, Fumitaka Mizoguchi, Hideyuki Iwai, Hiroyuki Hagiyama, Teruaki Oka, Nobuyuki Miyasaka.   

Abstract

We describe two cases of leflunomide-related interstitial pneumonia (IP). A 75-year-old woman with rheumatoid arthritis (RA) developed rapidly progressing IP 45 days after institution of leflunomide. She died of respiratory failure, and an autopsy revealed a mixed pattern of acute and organizing diffuse alveolar damage. A 69-year-old woman with RA also developed acute IP 3 months after institution of leflunomide. Methylprednisolone pulse therapy and cholestyramine ameliorated her IP. The implication of leflunomide in the pathogenesis of IP was suggested.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17039315     DOI: 10.1007/s10165-006-0506-2

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  3 in total

1.  Impact of interstitial lung disease on mortality of patients with rheumatoid arthritis.

Authors:  Dam Kim; Soo-Kyung Cho; Chan-Bum Choi; Jung-Yoon Choe; Won Tae Chung; Seung-Jae Hong; Jae-Bum Jun; Young Ok Jung; Tae-Hwan Kim; Tae-Jong Kim; Hye-Soon Lee; Joo-Hyun Lee; Jisoo Lee; Shin-Seok Lee; Dae-Hyun Yoo; Bo Young Yoon; Jin Woo Song; Sang-Cheol Bae; Yoon-Kyoung Sung
Journal:  Rheumatol Int       Date:  2017-07-26       Impact factor: 2.631

2.  Intrapulmonary rheumatoid nodules in a patient with long-standing rheumatoid arthritis treated with leflunomide.

Authors:  Ildiko Fanny Horvath; Antonia Szanto; Zoltan Csiki; Peter Szodoray; Margit Zeher
Journal:  Pathol Oncol Res       Date:  2008-04-08       Impact factor: 3.201

3.  High glucose/lysophosphatidylcholine levels stimulate extracellular matrix deposition in diabetic nephropathy via platelet‑activating factor receptor.

Authors:  Su-Xian Zhou; Dong-Mei Huo; Xiao-Yun He; Ping Yu; Yan-Hua Xiao; Chun-Lin Ou; Ren-Mei Jiang; Dan Li; Hao Li
Journal:  Mol Med Rep       Date:  2017-11-20       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.